Based on these findings, trastuzumab in combination with platinum-fluoropyrimidine chemotherapy was established as the standard-of-care first-line treatment in patients with HER2 IHC 2+/ISH positive or IHC 3+ tumours. This evidence concerns the gene ERBB2 and neoplasm.